BioSpace News Archive

OneOncology, the national partnership of independent community oncologists, said today that enrolling patients in clinical trials at its partner practices has slightly increased in March and April just as the COVID-19 pandemic hit our communities hardest.

Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has signed an exclusive agreement with Pacific GeneTech, a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in food safety and animal health, to license PGT’s Salmonella vaccine for poultry.

Tampa General Hospital is one of the first hospitals in Florida participating in several national research studies seeking effective ways to treat COVID-19

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will report financial results for the year ended December 31, 2019, on Thursday, April 23, 2020, and will host a conference call on the same day at 8 a.m. Eastern Time.

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious diseases.

ROE Dental Laboratory has refocused its significant 3D manufacturing capability and employee expertise to the production of essential medical supplies

Is there any specific drug to fight against COVID-19? When can we get access to the specific drug? These two questions are hard to answer for now. Developing the specific drug is quite tough. It is not practical when R&D works of new drugs usually takes too long and costs too much.

NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020

Cygnal Therapeutics today announced the publication of a new article in Cell, titled “Roadmap for the Emerging Field of Cancer Neuroscience.” Jonathan Hurov, Ph.D., who serves as Cygnal’s vice president of discovery biology and platforms, and multiple members of Cygnal’s Scientific Advisory Board are co-authors on the paper, among other scientists.

Revamped online member community gets update to align with rebranding of the association